ArticleCureus2026
Enhancing Compliance Through Local Anesthesia in Extended-Release Buprenorphine Therapy: A Report of Two Cases.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, treatment options for opioid use disorder have expanded significantly with the availability of a wide range of medication formulations. Extended-release buprenorphine is a long-acting, injectable medication used to treat moderate-to-severe opioid use disorder by providing a steady, continuous dose of buprenorphine over several weeks. Needle-related anxiety and injection-site pain are frequent adverse events that can significantly impede patient adherence to extended-release buprenorphine therapy. Topical and injectable anesthetics can enhance patient comfort and support greater adherence to the treatment protocol. This report presents two cases detailing a protocol to minimize pain from extended-release buprenorphine injections. This protocol utilizes a combination of topical anesthetic skin refrigerant (vapocoolant spray), local anesthetic, and an alkalizing agent, using specific techniques to minimize discomfort. After achieving adequate local anesthesia, extended-release buprenorphine therapy was well-tolerated, with participants reporting an essentially painless procedure. Topical and injectable anesthetics can improve patient comfort during extended buprenorphine administration, boosting adherence to opioid maintenance therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.